The present mini review aimed to summarize the existing knowledge regarding the beneficial and adverse effects of raloxifene in menopausal women. Methods: This study is a review of relevant publications about the effects of raloxifene on sleep disorder, depression, venous thromboembolism, the plasma concentration of lipoprotein, breast cancer, and cognitive function among menopausal women. Results: Raloxifene showed no significant effect on depression and sleep disorder. Verbal memory improved with administration of 60 mg/day of raloxifene while a mild cognitive impairment risk reduction by 33% was observed with administration of 120 mg/ day of raloxifene. Raloxifene was associated with a 50% decrease in the need for prolapse surgery. The result of a meta-analysis showed a significant decline in the plasma concentration of lipoprotein in the raloxifene group compared to placebo (standardized mean difference, -0.43; 10 trials). A network meta-analysis showed that raloxifene significantly decreased the risk of breast cancer (relative risk, 0.572; 95% confidence interval, 0.327-0.881; P = 0.01). In terms of adverse effects of raloxifene, the odds ratio (OR) was observed to be 1.54 (P = 0.006), indicating 54% increase in the risk of deep vein thrombosis (DVT) while the OR for pulmonary embolism (PE) was 1.05, suggesting a 91% increase in the risk of PE alone (P = 0.03). Conclusions: Raloxifene had no significant effect on depression and sleep disorder but decreased the concentration of lipoprotein. Raloxifene administration was associated with an increased risk of DVT and PE and a decreased risk of breast cancer and pelvic organ prolapse in postmenopausal women. (J Menopausal Med 2018;24:183-187)
Introduction
Menopause is a period in the life cycle of all women and is associated with hormonal changes, 1,2 that presents with different symptoms, including hot flashes, night sweat, vaginal atrophy, stress, apprehension and decreased libido. 3 Hormone replacement therapy (HRT) is a widely used therapeutic approaches to deal with menopausal symptoms. 4 Based on the report by the Women' s Health Initiative (WHI) the risk of cardiovascular events and breast cancer increase following the HRT regimen. 5 These serious complication have resulted in reduced desire to use HRT for menopausal women. According to a recent meta-analysis, tamoxifen can decrease the plasma lipoprotein concentration by 20%. 14 Daily administration of raloxifene at a dose of 120 mg has led to 33% reduction in the risk of mild cognition impairment. 6 According to the result of a network meta-analysis, raloxifene significantly decreased the risk of breast cancer.
15
Based on another meta-analysis, the use of raloxifene resulted in a 50% decrease in the need for prolapse surgery during 3 years follow up. 16 On the other hand, some adverse effect such as deep vein thrombosis (DVT) risk and pulmonary edema (PE) was caused by raloxifene. 
Materials and Methods
This study is a review of relevant publications about the effects of raloxifene on sleep disorder, depression and venous thromboembolism, plasma concentration of lipoprotein and cancer, breast cancer and cognition function among menopausal women.
Results
This mini review assessed the beneficial and adverse effects of raloxifene in menopausal women. Five studies included in this review (Table 1 ). These studies assessed the 
Raloxifene and POP
A meta-analysis was performed to assess the adverse effects of raloxifene and found that treatment with raloxifene was associated with 50% decrease in the need for prolapse surgery during a 3 year follow up period. The authors suggested that it is difficult to draw a certain conclusion based on the current findings and that there is a need for larger studies and higher quality of life. 6 
Raloxifene on breast cancer
A network meta-analysis showed that raloxifene significantly decreased the risk of breast cancer (summary relative 18 indicating a probable reduction in the protective effect of HDL against CVD after menopause. 19 Recently, a meta-analysis showed a 20% decrease in plasma lipoprotein in patients treated with tamoxifen. The effect of raloxifene on lipoprotein (a) is attributed to estrogen-like properties of raloxifene. 14 Yang et al. 6 found that raloxifene may act in a dose-dependent manner. They attributed this to the fact that raloxifene can easily cross the blood -brain barrier.
Adomaityte et al. 17 concluded that raloxifene could lead to an increased risk of DVT and PE. However, their metaanalysis had several limitations, that made it difficult to draw a conclusion. First, a wide CI was identified in their meta-analysis, second, in all included studies, DVT or PE was assessed as the secondary outcome. 
Conclusion
Raloxifene had no significant effect on depression and sleep disorder, but decrease the concentration of lipoprotein.
Raloxifene was associated with an increased risk of DVT and PE and a decreased risk of breast cancer and POP in postmenopausal women.
